China National Accord Medicines (SZSE:000028) LT-Debt-to-Total-Asset

: 0.03 (As of Mar. 2023)

View and export this data going back to 1993. Start your Free Trial

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. China National Accord Medicines's long-term debt to total assests ratio for the quarter that ended in Mar. 2023 was 0.03.

China National Accord Medicines's long-term debt to total assets ratio declined from Mar. 2022 (0.03) to Mar. 2023 (0.03). It may suggest that China National Accord Medicines is progressively becoming less dependent on debt to grow their business.

China National Accord Medicines LT-Debt-to-Total-Asset Historical Data

The historical data trend for China National Accord Medicines's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China National Accord Medicines Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

LT-Debt-to-Total-Asset

0.04

0.03

China National Accord Medicines Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
LT-Debt-to-Total-Asset																0.03	0.03	0.03	0.03	0.03

China National Accord Medicines LT-Debt-to-Total-Asset Calculation

China National Accord Medicines's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (A: Dec. 2022 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2022 )	/	Total Assets (A: Dec. 2022 )
	=	1344.904	/	42615.761
	=	0.03

China National Accord Medicines's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2023 is calculated as

LT Debt to Total Assets (Q: Mar. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2023 )	/	Total Assets (Q: Mar. 2023 )
	=	1328.788	/	47885.198
	=	0.03

China National Accord Medicines (SZSE:000028) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

China National Accord Medicines LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of China National Accord Medicines's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

China National Accord Medicines (SZSE:000028) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » China National Accord Medicines Corp Ltd (SZSE:000028) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

200028:China

Address

No. 15, Ba Gua Si 4th Road, Accord Pharmaceutical Building, Futian District, Guangdong Province, Shenzhen, CHN, 518029

Website

http://www.szaccord.com.cn

China National Accord Medicines Corp Ltd develops and manufactures pharmaceuticals in China. The company engaged in the wholesale of Chinese patent drugs, traditional Chinese medicines, chemical medicine preparations, antibiotics, biochemical drugs and cerebrovascular system drugs. It operates through the following segments: The Head office segment engages in investing and managing the business; The Pharmaceutical Distribution segment engages in the distribution of medicine and pharmaceutical products to customers, including hospitals, other distributors, retail drug stores, and clinics, and Retail pharmacy segment, which is managing the operation of Guoda Pharmacy. It generates maximum revenue from the Pharmaceutical Distribution segment.

China National Accord Medicines (SZSE:000028) Headlines

No Headlines